Everything below concerns 垂体受体. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-07-20. Numbers and descriptions here follow the published literature rather than marketing material.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | N-terminal trans-3-hexenoyl group |
| Approximate mass | About 5.1 kDa | Derived from the peptide sequence |
| Primary target | Pituitary GHRH receptor | Somatotroph cells of the anterior pituitary |
| Downstream marker | IGF-1 | Measured indirectly in circulation |
研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。
tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。
作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶，升高细胞内 cAMP，再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点，生长激素仍以脉冲方式分泌，而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生，构成完整的生长激素轴响应。
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Springer's lab screened for such activity in cell line supernatants, purified and sequenced the protein, and found that stromal derived factor (SDF-1), previously defined as a growth factor for B cells, was a potent chemoattractant for both B and T cells. SDF-1 activated an orphan GPCR, later named CXCR4, which was also the co-receptor for T-cell-tropic HIV; SDF-1 further blocked infection of T cells by HIV. SDF-1 (CXCL12) is also a chemoattractant for CD34+ hematopoietic stem cells and regulates their movement from bone marrow to the bloodstream. Based on these discoveries, plerixafor (Mozobil) was developed as an antagonist of CXCR4 and is approved, in combination with filgrastim, for use in mobilizing hematopoietic stem cells in patients with multiple myeloma or non-Hodgkin lymphoma. In later retrospective discussion, Springer framed the three steps in leukocyte emigration into inflammatory sites as an “area code” model, emphasizing that each step requires a cognate receptor–ligand interaction and therefore provides multiple intervention points (selectins and ligands; GPCRs and ligands; integrins including LFA-1, α4β1, α4β7 and endothelial ligands). He argued that the size of the target space exceeded what could be pursued in an academic laboratory and helped motivate company formation.
In 2009, IGN named Newell one of the top 100 game creators, writing that it was "almost impossible to gauge" Valve's influence on game design, technology and the video games industry. In December 2010, Forbes listed Newell as "A Name You Need to Know", primarily for his work on Steam and partnerships with multiple major developers. In 2013, Newell was added to the Academy of Interactive Arts & Sciences Hall of Fame and received the BAFTA Fellowship for his contributions to the video game industry. According to Josh Weier, the project lead for Portal 2 (2011), Newell became less involved in game development after Portal 2 as many developers would blindly agree with his ideas due to his position. As of 2024, Newell had become less involved in Valve and was spending more time on personal projects.
=== STC2 === STC2 was discovered from the human DNA database. In human STC2 is produced by STC2 gene which is located in the long arm of human chromosome 5 (position q35.1). It is very different from STC1 and show only 34% similarity. STC2 mRNA is found in pancreas, kidney, spleen, and skeletal muscles.
Both provinces of Negros are interconnected by major inter-provincial roads. In Bacolod, there are two main roads, namely Lacson Street to the north and Araneta Street to the south. Cities, especially the provincial capitals of Bacolod and Dumaguete, are being served by jeepneys and taxis. Tricycles are mainly used for short-distance travel, and is common in city barangays, smaller cities and towns. Bus stations are present in major cities and towns within the region. Vallacar Transit Corporation, which operates the Ceres buses, serves the whole island of Negros. There are regularly scheduled fast ferry and roll-on/roll-off services for the island region's coastal cities and towns.
Sources: en.wikipedia.org
== Chemistry == BmKAEP is an inhibitory β-toxin and thus, a Na+ channel inhibitor. As with other mammal and insect toxins, BmKAEP is classified according to species and mechanism of action. BmKAEP is a 61-amino-acid protein derived from an 85-amino-acid precursor. The mature protein contains 8 cysteine residues that establish 4 disulfide bridges (4C-C). Despite its high homology with other depressant toxins, BmKAEP differs from them at residues 6, 7 and 39, which is thought to be important in determining its unique function. Its lysine residue, at position 51, also has a special feature: it interacts with mammalian Na+ channels.
The Agong at the time, Ahmad Shah of Pahang, agreed with the proposals in principle, but baulked when he realised that the proposal would deem Sultans to assent to laws passed by state assemblies. Supported by the Sultans, the Agong refused to assent to the constitutional amendments, which had passed both houses of Parliament with comfortable majorities. When the public became aware of the impasse, and the Sultans refused to compromise with the government, Mahathir took to the streets to demonstrate public support for his position in mass rallies. The press took the side of the government. A large minority of Malays, including conservative UMNO politicians, and an even larger proportion of the Chinese community supported the Sultans. After five months, the crisis was resolved, as Mahathir and the Sultans agreed to a compromise. The Agong retained the power to declare a state of emergency. However, if he refused to assent to a bill, the bill would return to Parliament, which could then override Agong's veto. In 1984, Mahathir was re-elected unopposed as UMNO president for a second term.
==== Antithrombotic activity ==== Honokiol inhibits platelet aggregation in rabbits in a dose-dependent manner, and protects cultured RAEC against oxidized low density lipoprotein injury. Honokiol significantly increases the prostacyclin metabolite 6-keto-PGF1alpha, potentially the key factor in honokiol's antithrombotic activity.
== Overdose == Lorcaserin can produce hallucinogenic effects and other side effects with overdose. This can occur with single doses that are only 2- to 6-fold the usual single therapeutic dose. The effects are thought to be serotonergic psychedelic effects and are believed to be mediated by activation of the serotonin 5-HT2A receptor.
== Gameplay == The player controls the main character (Chell in both single player campaigns, or Atlas and P-Body in the Portal 2 co-op campaign) from a first-person view, running, jumping, and interacting with switches or other devices. The player-characters are able to withstand large drops, but can be killed by falling in the toxic water of the facility, crushed to death, passing through laser grids, or fired on repeatedly by turrets. Both games are generally divided into a series of test chambers; other sections of the game are more exploratory areas that connect these chambers. Each chamber has an exit door that must be reached, often requiring that certain conditions have been met such as having weighed down a large button with a "Weighted Cube", effectively a crate. These puzzles require the use of the Aperture Science Handheld Portal Device, the portal gun. The gun can be upgraded shoot two portals, colored differently for identification, on any flat surface that is painted with a specific paint containing moon dust. Once both portal ends are placed, the player can walk the character between them, or carry objects with the portal gun through them. Portal ends can be re positioned as often as necessary, but certain actions, such as walking through "emancipation grills" or moving a surface with a portal will cause the portals to dissipate.
Sources: en.wikipedia.org
Sitagliptin was approved by the US Food and Drug Administration (FDA) in October 2006, and is sold under the brand name Januvia. In April 2007, the FDA approved an oral combination of sitagliptin/metformin sold under the brand name Janumet. In October 2011, the FDA approved an oral combination of sitagliptin/simvastatin sold under the brand name Juvisync. The extended release version of sitagliptin/metformin was approved in February 2012.
==== Cone snail and fish insulin ==== Conus geographus produces a distinct form of insulin that is more similar to fish insulin protein sequences than to insulin from more closely related molluscs, suggesting convergent evolution, though with the possibility of horizontal gene transfer.
The partition coefficient is defined at a specified temperature and, if applicable, pH of the aqueous phase. Partition coefficients are very important in pharmacology because they determine the extent to which a substance can pass from the blood (an aqueous solution) through a cell wall which is like an organic solvent. They are usually measured using water and octanol as the two solvents, yielding the so-called octanol-water partition coefficient. Many pharmaceutical compounds are weak acids or weak bases. Such a compound may exist with a different extent of protonation depending on pH and the acid dissociation constant. Because the organic phase has a low dielectric constant the species with no electrical charge will be the most likely one to pass from the aqueous phase to the organic phase. Even at pH 7–7.2, the range of biological pH values, the aqueous phase may support an equilibrium between more than one protonated form. log p is determined from the analytical concentration of the substance in the aqueous phase, that is, the sum of the concentration of the different species in equilibrium.
Metabolites produced from vitamin D2 tend to bind less well to the vitamin D-binding protein. Vitamin D3 can alternatively be hydroxylated to calcifediol by sterol 27-hydroxylase, an enzyme coded for by gene CYP27A1, but vitamin D2 cannot. Ergocalciferol can be directly hydroxylated at position 24 by the enzyme coded for by CYP27A1. This hydroxylation also leads to a greater degree of inactivation: the activity of calcitriol decreases to 60% of original after 24-hydroxylation, whereas ercalcitriol undergoes a 10-fold decrease in activity on conversion to ercalcitetrol.
Alternatives to the predominantly punitive, law enforcement approach to the war on drugs in the US fall under two broad categories: a public health orientation built around education, prevention and treatment, and decriminalization or legalization with regulation similar to the handling of alcohol. Jefferson Fish has edited scholarly collections of articles offering a wide variety of public health-based and rights-based alternative drug policies.
Sources: en.wikipedia.org
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.
The N-terminal modification reduces cleavage by circulating peptidases, so the peptide persists longer than native GHRH. That persistence is the main rationale for the synthetic design. Comparative half-life values in humans are reported in regulatory review documents rather than in general reference literature.
Reductions in visceral adipose tissue have been measured in controlled studies of defined populations. Whether the effect generalizes to other groups and persists after treatment stops is less clear. Longer-term outcome data remain limited.
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.